Legal Advantage Investments’s DexCom DXCM Stock Holding History

Legal Advantage Investments’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-9,300	Closed	-$860K	–	78
2020 Q4	$860K	Buy	+9,300	New	+$830K	0.67%	45

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Legal Advantage Investments's DXCM Position: Q1 2021 in Review

Legal Advantage Investments sold out of DexCom (DXCM) in Q1 2021, closing a stake of 9,300 shares — an estimated $860K sold.

Legal Advantage Investments first reported a position in DXCM in Q4 2020 and held it in 1 quarter. The position peaked at $860K in Q4 2020. 730 funds tracked by Wall St. Rank hold DXCM as of Q1 2021.

Legal Advantage Investments reported no remaining DexCom position as of Q1 2021 after selling out during the quarter.
Legal Advantage Investments sold 9,300 DexCom shares in Q1 2021, an estimated $860K.
Legal Advantage Investments first reported a position in DexCom in Q4 2020 and held it in 1 quarter.
Legal Advantage Investments's DexCom position peaked at $860K in Q4 2020.
730 funds tracked by Wall St. Rank held DexCom as of Q1 2021.

Based on Legal Advantage Investments's 13F filing for Q1 2021, filed 6 May 2021.